About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials | 4,050 Studies Recruiting

Clinical TrialsOvarian Cancer

Ovarian Cancer Clinical Trials

Browse 4,050 clinical trials for ovarian cancer. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 401-420 of 4,050 trials

TerminatedStudy of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian CancerThis study will determine the value of adding AMG 479 (fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin first line chemotherapy in patients with…NCT00718523·Alhambra, California and 54 others

Related Searches

ovary cancertrials

Data from ClinicalTrials.govTerms

RecruitingPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerThis is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV…NCT05739981·Baltimore, Maryland and 3 others

WithdrawnSafety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersThe purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated…NCT04464967

RecruitingA Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant…NCT05877599·Gilbert, Arizona and 19 others

RecruitingIntegrated Cancer Repository for Cancer ResearchThe iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal…NCT02012699·Greenwood Village, Colorado and 41 others

CompletedHigh Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower LimbsThe aim of the study is to explore the feasibility and safety of High Intensity Interval Training on a stationary bike for patients with lymphedema in the lower limbs and the role…NCT03653819·Herlev

CompletedVitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian CancerThis study will evaluate serum vitamin D (25(OH)D) and serum leptin levels at the time of diagnosis of ovarian, primary peritoneal, and/or fallopian tube cancer as well as vitamin…NCT03028519·Oklahoma City, Oklahoma

UnknownA Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyThis is a Prospective,Single-Center, Single-Arm, Phase 2 study to evaluate the efficacy and safety of Fluzoparib Combined With QL1101, as maintenance treatment, in patients with…NCT05585281·Shenyang

CompletedAZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube CancerThis phase II trial is studying how well AZD2171 works in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer.NCT00275028·Boston, Massachusetts

Not yet recruitingProspective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian CancerAs one of the gynecological malignancies with the highest incidence and mortality rates worldwide, ovarian cancer treatment faces the significant challenge of platinum-resistant…NCT07314619·Zhengzhou, Henan

TerminatedComparison of Standard of Care or Treatment on ProtocolPatient will choose to either receive the standard of care according to National Comprehensive Cancer Network (NCCN) or approved guidelines for their condition or to be treated…NCT01010334·Albuquerque, New Mexico

CompletedObservation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian CancerInvestigators propose to assess,the safety and tolerability profile (number of participants with adverse events) of bevacizumab (Avastin) when added to chemotherapy as front-line…NCT01982500·Heraklion, Crete and 5 others

UnknownCA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving TamoxifenRATIONALE: Estrogen may cause the growth of ovarian cancer cells. Hormone therapy using tamoxifen may fight ovarian cancer by blocking the use of estrogen by the tumor cells.NCT00305838·Burton-on-Trent, England and 23 others

RecruitingDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian CancerThis study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in…NCT07589543·Shenzhen, Guangdong

CompletedSentinel Node Detection in Clinical Early Stage Ovarian CancerAs most cancers, ovarian cancer also spreads to regional lymph nodes.NCT01734746·Maastricht, Limburg

UnknownTreatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01RATIONALE: Treatment for pediatric extracranial germ cell tumors may cause side effects and secondary cancers later in life.NCT00436774·Dublin and 12 others

AvailableExpanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer PatientsAVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO.NCT05974410

UnknownContrast-Enhanced Ultrasound Ability in the Characterization of Ovarian MassesThis study intends to assess the ability of contrast-enhanced ultrasound in the detection of benign and malignant ovarian masses compared to unenhanced ultrasound.NCT00248820·Tours

UnknownClinical Study of Pan-cancer DNA Methylation Test in PlasmaWe intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex…NCT05685524·Zhengzhou, Henan

RecruitingA Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerThis is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or…NCT05128825·Mobile, Alabama and 85 others

PreviousPage 21 of 203Next